Advancing TET Inhibitor Development: From Structural Insights to Biological Evaluation

Area of Science:

• Epigenetics and Molecular Biology
• Biochemistry
• Structural Biology

Background:

• Ten-eleven translocation (TET) methylcytosine dioxygenases are key epigenetic regulators involved in DNA demethylation.
• Dysfunctional TET activity, particularly TET2 loss, is implicated in hematopoietic malignancies, leading to DNA hypermethylation.
• Understanding TET biology is critical for deciphering disease pathogenesis and developing new therapies.

Purpose of the Study:

• To advance the development of TET inhibitors through an integrated computational and experimental approach.
• To identify and characterize novel chemical tools for exploring TET enzyme function.
• To lay the foundation for TET-centered therapeutic strategies.

Main Methods:

• Integrated pipeline combining protein X-ray crystallography, molecular modeling, and pharmacophore analysis.
• Synthesis and evaluation of 8-hydroxyquinoline (8-HQ) derivatives.
• Biochemical assays to assess inhibitor potential and chemical tool utility.

Main Results:

• A robust computational pipeline was established for TET inhibitor development.
• A series of 8-hydroxyquinoline derivatives were synthesized and validated.
• These derivatives show potential as chemical tools for further TET research.

Conclusions:

• The developed pipeline provides a strong framework for advancing TET inhibitor design.
• The synthesized 8-HQ derivatives serve as valuable chemical probes for studying TET function.
• These advancements pave the way for novel TET-targeted therapeutic interventions in epigenetic disorders.